Subsidiaries Silence EContact Us>
Silence Therapeutics Silence Therapeutics
▼
210.00p (0.00p)
Vol: 11092
(15-minute delayed)
View full stock quote


  • Home
  • About Us
  • Platform Technologies
  • Pipeline
  • Collaborations
  • Investor Relations
  • News & Events
  • RNAi Hub
  • Menu
  • About Us
    • Overview
    • Strategy
    • History
    • Management
    • Board Of Directors
    • Scientific Advisory Board
    • Careers
  • RNAI Platform
    • Overview
    • Delivery Platform
    • RNAi Platform
    • RNA Interference
    • Intellectual Property
    • Publications
    • Glossary
  • Pipeline
    • Overview
    • Pre-Clinical development
  • Collaborations
    • Overview
    • Silence's Strengths
    • Partnerships
    • Partnering Opportunities
  • Investor Relations
    • Overview
    • Press Releases
    • Reports and Disclosures
    • Analyst Coverage
  • News & Events
    • Press Releases
    • Events
    • In the News
    • Publications
  • RNAi Hub
  • Contact
 
 

A leading RNAi
therapeutics product
and technology platform
company with proprietary delivery systems.

Pipeline Review Our Pipeline >
  • Silence TV Youtube

    View Dr. Klaus Giese's presentation slides here

    Silence News

    • 02.05.13

      Holding in Company

    • 02.05.13

      Holding in Company

    • 02.05.13

      Holding in Company

    • 19.09.12Silence Twitter

      Read more on our recent appointment of Michael Khan as Chief Medical Adviser on our Board of Directors via http://t.co/2n06ndLl
      240 days ago


    Twitter Follow Us On Twitter >
  • RNAi Therapeutics

    Silence Therapeutics has created two powerful platforms and a strong pipeline to exploit the Company's impressive technological know-how and IP.

    RNAi Platform

    Delivery Platform

    Products Pipeline

    Combined, the RNAi and delivery platforms enable the development of multiple products to multiple drug targets allowing the development of novel therapeutics to diseases with high unmet medical need.

    Core Values

    Silence Therapeutics wants to capitalise on these, its core competencies, to bring to market the next generation of therapeutic agents (RNAi therapeutics) alongside current small molecule and biological therapies.

    J Learn More >
  • RNAi Hub

    The RNAi Hub is a comprehensive resource for people interested in the latest developments in RNAi Therapeutics. The RNAi Hub regroups in one location the news from the RNAi Therapeutics field, with a particular focus on the following areas of interest:

    News Events
    Publications Companies
    Clinical Trials  
    • 17.05.13

      Alnylam Presents Key Pre-Clinical Proof-of-Concept Data for ALN-AS1, an RNAi Therapeutic Targeting Aminolevulinate Synthase-1 (ALAS-1) for the Treatment of Porphyria

    • 17.05.13

      PI3K pathway dependencies in endometrioid endometrial cancer cell lines.

    • 17.05.13

      Raf kinase inhibitor protein inhibits esophageal cancer cell invasion through downregulation of matrix metalloproteinase expression.

    • 17.05.13

      20-hydroxyecdysone upregulates Atg genes to induce autophagy in the Bombyx fat body.



    b RNAi Hub >

Quick Links

  • Home
  • About Us
  • Platform Technologies
  • Pipeline
  • Collaborations
  • Investor Relations
  • News & Events
  • RNAi HUB
  • Site Map

Contact

3 Shortlands
Hammersmith
London W6 8DA
United Kingdom


Tel:+44 (0) 333 9880 140
Fax:+44 (0) 795 731 8494
Silence Therapeutics

Copyright © 2013 Silence Therapeutics.
All rights reserved.

Terms of Use
Forward-Looking Statement